US4472500A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Rat myeloma cell lines
Assignee: BTG International Ltd
•
Filing: 1981-07-07
•
Granted: 1984-09-18
•
Expires: 2001-07-07
Abstract
Abstract A rat myeloma cell line which does not express an immunoglobulin chain, YB2/3.0.Ag.20, is prepared from the cell line Y3-Ag 1.2.3 via a hybrid myeloma cell line. This cell line, and variants thereof prepared by passaging and/or cloning the line, may be fused with immunocyte cells from an animal sensitized to an immunogen to produce hybrid myeloma cell lines which provide a source of monoclonal antibodies to said immunogen.
Inventors
- 👤 Cesar Milstein
- 👤 Bruce W. Wright
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 11:31
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/14; C12; C12N; C12N5/00; C12N5/10; C12N5/12; C12N5/16; C12N5/163; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
6 words
The rat myeloma cell line YB2/3.0.Ag.20.
Claim 2
Dependent Claim
6 words
The rat myeloma cell line YB2/3.0.Ag.20.
Claim 3
Dependent Claim
21 words
A rat myeloma cell line being a variant of the cell line YB2/3.0.Ag.20 prepared by passaging and/or cloning cell line YB2/3.0.Ag.20.
Claim 4
Dependent Claim
21 words
A rat myeloma cell line being a variant of the cell line YB2/3.0.Ag.20 prepared by passaging and/or cloning cell line YB2/3.0.Ag.20.
Claim 5
Dependent Claim
18 words
A hybrid myeloma cell line derived from a parent myeloma cell line according to claim 1 or 2.
Claim 6
Dependent Claim
31 words
A hybrid myeloma cell line, prepared through the fusion of YB2/3.0.Ag.20 or a variant thereof prepared by passaging and/or cloning YB2/3.0.Ag.20, with immunocyte cells from an animal sensitized to an antigen.
Claim 7
Dependent Claim
31 words
A hybrid myeloma cell line, prepared through the fusion of YB2/3.0.Ag.20 or a variant thereof prepared by passaging and/or cloning YB2/3.0.Ag.20, with immunocyte cells from an animal sensitized to an antigen.
Claim 8
Dependent Claim
19 words
An in vitro cell culture system comprising cells according to claim 1 or 2 in a nutrient medium therefor.
Claim 9
Dependent Claim
28 words
An in vitro cell culture system according to claim 5, comprising a rat myeloma cell line having the characteristics of the cells YB2/3.0.Ag.20 in a nutrient medium therefor.
Claim 10
Dependent Claim
43 words
A cell fusion system which comprises cells of a cell line according to claim 2 or 3 and immunocyte cells from an animal sensitized to an immunogen in a nutrient culture medium therefor with an agent which promotes the fusion of said cells.
Claim 11
Dependent Claim
15 words
A cell fusion system according to claim 7 in which the cell line is YB2/3.0.Ag.20.
Claim 12
Dependent Claim
16 words
A cell fusion system according to claim 8, in which the immunocyte cells are spleen cells.
Claim 13
Dependent Claim
16 words
A cell fusion system according to claim 8, in which the immunocyte cells are rat cells.
Claim 14
Dependent Claim
18 words
A cell fusion system according to claim 8, in which the agent which promotes fusion is polyethylene glycol.
Claim 15
Dependent Claim
36 words
A cell fusion system according to claim 7, which comprises cells of the cell line YB2/3.0.Ag.20 and spleen cells from a rat sensitized to an immunogen in a nutrient culture medium therefor together with polyethylene glycol.
Claim 16
Dependent Claim
15 words
A process for producing a rat myeloma cell line which comprises passaging and/or cloning YB2/3.0.Ag.20.
Claim 17
Dependent Claim
15 words
A process for producing a rat myeloma cell line which comprises passaging and/or cloning YB2/3.0.Ag.20.
Claim 18
Dependent Claim
20 words
A process according to claim 13 in which said rat myeloma cell line is obtained by passaging YB2/3.0.Ag.20 in vivo.
Claim 19
Dependent Claim
13 words
A process according to claim 14, in which the passaged cells are cloned.
Claim 20
Dependent Claim
18 words
A process according to claim 14, in which the cell line is passaged through a plurality of rats.
Claim 21
Dependent Claim
36 words
A process according to claim 16, in which the rats are of the Lou strain, the variant having the ability to grow readily in a pure Lou strain rat in addition to an A0×Lou hybrid rat.
Claim 22
Dependent Claim
25 words
A process according to claim 13, in which the rat myeloma cell line is obtained by cloning a plurality of cells of the cell line.
Claim 23
Dependent Claim
45 words
A process for producing a hybrid myeloma cell line which comprises fusing cells of a cell line according to any of claims 1 or 2, with immunocyte cells from an animal sensitized to an immunogen using an agent which promotes the fusion of said cells.
Claim 24
Dependent Claim
20 words
A process according to claim 19, in which the animal from which the immunocyte cells are derived is a rat.
Claim 25
Dependent Claim
39 words
A process for the production of antibodies which comprises culturing cells of a hybrid myeloma cell line according to claim 5 in an in vitro or in vivo culture medium therefor and thereafter isolating the antibodies from said medium.
Claim 26
Dependent Claim
50 words
An antibody production process which comprises preparing a hybrid myeloma cell line by the fusion of cells of the cell line YB2/3.0.Ag.20 with immunocyte cells sensitized to an immunogen and culturing the hybrid in an in vitro or in vivo culture medium therefor to produce antibodies against the sensitizing immunogen.
Claim 27
Dependent Claim
50 words
An antibody production process which comprises preparing a hybrid myeloma cell line by the fusion of cells of the cell line YB2/3.0.Ag.20 with immunocyte cells sensitized to an immunogen and culturing the hybrid in an in vitro or in vivo culture medium therefor to produce antibodies against the sensitizing immunogen.
Claim 28
Dependent Claim
46 words
A process according to claim 22 in which cells of the hybrid myeloma cell line are cultured by inoculating a rat with the hybrid to thereby produce a solid or ascitic tumour, and thereafter isolating the antibodies from the serum and/or ascitic fluid of the rat.
References Cited (Backward Citations)
GB2039948A
Cited
US4350683A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-18 | 1988-03-19 | 1988-09-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-18 | 1992-03-19 | 1992-09-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-18 | 1996-03-19 | 1996-09-18 | $7700.00 | Window Closed / Lapsed |